Loading…
← CockpitCompetitor Analysis › EL.PA EssilorLuxottica SAOpen in the cockpit ↗

EssilorLuxottica SAEL.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Medical Specialties

World's largest eyewear company: makes prescription lenses (Essilor/Varilux) and designs/sells sunglasses and frames (Ray-Ban, Oakley).

≈ A vertically integrated Warby Parker + Zeiss + Ray-Ban combinedMomentum leader 91
Mkt cap
$91.9B
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$181M
20-day average traded
Fwd P/E
24.8×
forward earnings
ROIC−WACC
-4.0 pp
WACC 9.0%
Hurdle
+4 pp
Req g minus delivered
Official | Implied
A+ / AAA
agencies · bond market
Next earnings
91 days
17 Feb 2027
Close · EUR€180.80
1D+1.1%
1W-1.0%
1M+20.1%
3M+10.8%
6M+5.1%
YTD-33.0%
1Y-40.9%
ATR %3.1%
52w lowhigh43.0% off high

What EssilorLuxottica does

World's largest eyewear company: makes prescription lenses (Essilor/Varilux) and designs/sells sunglasses and frames (Ray-Ban, Oakley).

Sells lenses mainly to opticians, who fit them to customers, and frames and sunglasses through its own retail chains and through making eyewear for fashion houses under licence. It was formed by the 2018 merger of lens maker Essilor and frame maker Luxottica, and bought the optical retailer GrandVision in 2021. The Del Vecchio family holding is the largest shareholder.

In one line: A vertically integrated Warby Parker + Zeiss + Ray-Ban combined.

Products and services

  • Prescription lenses (Varilux, Essilor)
  • Sunglasses & frames (Ray-Ban, Oakley, Persol)
  • Licensed fashion eyewear (Chanel, Prada, etc.)
  • Optical retail chains
  • Smart glasses (Ray-Ban Meta)

Customers

  • Opticians & optometrists
  • Retail consumers
  • Licensed fashion brands

Where it sits in the supply chain

  • Eyewear/optical
  • Lens manufacturing + frame design
  • Retail optical (LensCrafters, Sunglass…

What could go right

  • Aging population/vision correction demand
  • Smart glasses category growth
  • GrandVision retail integration

What could go wrong

  • Antitrust scrutiny of scale
  • Currency/tariff exposure
  • Fashion licence renewal risk

Moat: wide (scale, brand, distribution). Owns both lens manufacturing and the dominant sunglass/frame brands plus retail distribution end-to-end.

Headquarters: Charenton-le-Pont, France · Founded: 2018 · Employees: 203,791

Named competitors

EssilorLuxottica at a glance

Size EssilorLuxottica (EL.PA) is a France Health Care company (Medical Specialties) with a market value of $91.9B, the 12th largest of 206 France companies the cockpit tracks. Shares closed at €180.80 on 18 Nov 2026.

Performance Over six months the shares gained 5.1%, against +26.4% for the median peer and -2.1% for the France market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 7.5% over the last twelve months (peer median +8.7%); the operating margin is 12.4% (peer median 21.2%).

Valuation It trades at 24.8× forward earnings against a peer median of 25.4× (10th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.0 points below its cost of capital (9.0% WACC).

Credit EssilorLuxottica has 6 bonds outstanding ($7.49B), rated A+ by the agencies and trading like AAA at a weighted spread of 34 bp.

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 126EL.PA 104
Six months, rebased to 100: EssilorLuxottica against the median of its 20 peers (local-currency closes).

EssilorLuxottica financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€29.3B€28.5B€26.5B€25.4B€24.5B
Revenue growth—+7%+4%+4%—
Gross profit€17.8B€17.3B€16.8B€16.1B€15.6B
EBITDA€6.75B€6.54B€6.44B€6.24B€6.18B
Net income€2.49B€2.31B€2.36B€2.29B€2.15B
Free cash flow€4.14B€4.06B€3.69B€3.33B€3.21B
Capital expenditure€1.15B€1.52B€1.52B€1.53B€1.57B
Total debtn/a€14.4B€13.2B€11.7B€12.2B

Quarterly statements and history in the cockpit →

EssilorLuxottica competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+10%+20%SYKMDTBSXEWBDXISRGIDXXSHLDHRMDLNA7741ABTWATGEHCALCMTDRMD300760TMOEL.PA6-month return →1-month return →
Up and to the right = strong over both horizons. EssilorLuxottica is the large dot.

Fundamentals: revenue growth against valuation

0%+5%+10%+15%+20%20×30×SYKMDTBSXEWBDXISRGIDXXSHLDHRMDLNA7741ABTWATGEHCALCMTD300760TMOEL.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. EssilorLuxottica is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%10%20%30%SYKMDTBSXEWBDXISRGIDXXSHLDHRMDLNA7741ABTWATGEHCALCMTDRMD300760TMOEL.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. EssilorLuxottica is the large dot.

EssilorLuxottica competitors and peer comparison

Head to head with its named competitors (EL.PA vs 7741.T vs SFL.MI vs MONC.MI)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
EssilorLuxottica EL.PA$91.9B+5%+8%12%24.8×18.4%
Hoya 7741.T$49.0B-16%+13%32%27.7×14.1%
Safilo SFL.MI$953M+42%-4%9%15.8×1.3%
Moncler MONC.MI$12.2B-21%+3%29%17.7×9.2%
Warby Parker WRBY$3.50B+15%+10%0%56.2×n/a

How EssilorLuxottica compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

EssilorLuxottica against its 20 peers (data as of 18 Nov 2026)
MeasureEL.PAPeer medianRank in peer set
1-month return+20.1%+5.5%2nd highest of 21
6-month return+5.1%+26.4%5th lowest of 21
Distance from 52-week high-43.0%-8.0%2nd lowest of 21
Revenue growth (TTM)+7.5%+8.7%8th lowest of 21
Operating margin12.4%21.2%4th lowest of 21
Forward P/E24.8×25.4×10th cheapest of 21
Growth the price implies (Req g, 7 yrs)18.4%15.0%8th most demanding of 21
Growth delivered (Del g)+14.6%+6.4%3rd highest of 21
Hurdle (Req g minus delivered)+3.8 pp+6.1 pp8th least demanding of 21
ROIC minus cost of capital-4.0 pp+3.7 pp2nd lowest of 21
EV / EBITDA14.5×19.3×6th cheapest of 20
Net debt / EBITDA2.0×1.9×9th most indebted of 20
Bond spread34 bp75 bptightest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
EssilorLuxottica EL.PAFrance$91.9B+5%+8%12%24.8×18.4%+14.6%
Stryker SYKUnited States$121B-1%+8%25%19.9×10.7%+11.8%
Medtronic MDTUnited States$129B+30%+10%20%16.8×9.1%+3.8%
Boston Scientific BSXUnited States$63.3B-23%+9%21%14.1×5.8%+15.2%
Edwards Lifesciences EWUnited States$60.5B+27%+13%29%32.3×17.1%+6.7%
Becton Dickinson BDXUnited States$58.9B+48%-7%16%16.3×-1.6%+0.3%
Intuitive Surgical ISRGUnited States$146B-6%+20%32%34.8×29.6%+18.2%
Idexx Laboratories IDXXUnited States$55.0B+26%+12%32%42.9×29.0%+9.7%
Siemens Healthineers SHL.DEGermany$53.7B+27%+1%14%18.9×9.6%+5.6%
Danaher DHRUnited States$161B+34%+6%21%25.1×20.8%+2.0%
Medline MDLNUnited States$51.5B+8%+12%6%25.6×15.9%+9.9%
Agilent Technologies AUnited States$50.0B+56%+9%24%27.0×23.3%+5.4%
Hoya 7741.TJapan$49.0B-16%+13%32%27.7×14.1%+11.6%
Abbott Laboratories ABTUnited States$181B+18%+10%14%17.9×16.5%+5.1%
Waters WATUnited States$45.8B+37%+81%10%29.1×48.1%+6.0%
GE HealthCare GEHCUnited States$37.8B+30%+7%14%15.6×5.0%+3.7%
Alcon ALC.SWSwitzerland$36.9B+18%+1%12%21.5×12.2%+6.1%
Mettler Toledo MTDUnited States$34.6B+60%+7%29%33.7×20.1%+5.5%
ResMed RMDUnited States$34.1B+16%+9%34%19.7×5.7%+12.1%
Shenzhen Mindray Bio-Medical Electronics 300760.SZChina$33.6B+15%+5%28%27.3×1.0%+9.7%
Thermo Fisher Scientific TMOUnited States$257B+53%+8%19%25.7×21.3%+6.7%

EssilorLuxottica bonds and credit

EssilorLuxottica has 6 bonds outstanding with $7.49B face value. The agencies rate it A+; its bonds trade like AAA. Weighted yield 3.67%, a spread of 34 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are EssilorLuxottica's main competitors?
Named competitors: Carl Zeiss (private) (private or unlisted), Hoya Corp (7741.T), Safilo Group (SFL.MI), Moncler (fashion eyewear overlap) (MONC.MI), Warby Parker (WRBY). The cockpit's measured peer set (industry) also includes Stryker (SYK), Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Becton Dickinson (BDX), Intuitive Surgical (ISRG).
Is EssilorLuxottica expensive compared with its peers?
On forward p/e it trades at 24.8× against a peer median of 25.4×, 10th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has EssilorLuxottica stock performed?
Over six months to 18 Nov 2026 the shares returned +5.1% against +26.4% for the median peer; over one year -40.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.